After Years of Trial and Error, Biotech is Seeing More Successes Than Ever

John Crowley, Chairman & Former CEO of Amicus Therapeutics, joins the show to discuss the strides the biotech industry has made in therapies for rare genetic diseases and the industry landscape going forward.

This interview originally aired as part of Wharton Business Daily's Business of Healthcare special.

Hosted on Acast. See acast.com/privacy for more information.